Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD plus Cisplatin in Advanced Poorly Differentiated Thyroid Carcinoma
NCT03387943Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in poorly differentiated thyroid carcinoma (PDTC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on NCT03387943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387943.